The Fox(o) and the HDAC
Open Access
- 23 April 2020
- journal article
- editorial
- Published by American Society of Hematology in Blood
- Vol. 135 (17), 1416-1417
- https://doi.org/10.1182/blood.2020005291
Abstract
In this issue of Blood, Long et al1 describe a FOXO1/3-HDAC8-p53–mediated pathway leading to resistance and persistence of FLT3-ITD+ acute myeloid leukemia (AMLThis publication has 10 references indexed in Scilit:
- FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemiaBlood, 2020
- Mechanisms of drug resistance in acute myeloid leukemiaOncoTargets and Therapy, 2019
- Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanismsNature Communications, 2019
- Targeting the bone marrow microenvironment in acute leukemiaLeukemia & Lymphoma, 2018
- A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic programBlood, 2017
- FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid LeukemiaCancer Research, 2016
- New and emerging HDAC inhibitors for cancer treatmentJCI Insight, 2014
- Acute myeloid leukemia: 2013 update on risk‐stratification and managementAmerican Journal of Hematology, 2013
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemiaNature, 2012
- Unravelling the tumor-suppressive functions of FOXO proteinsTrends in Cell Biology, 2008